{{Rsnum
|rsid=2229207
|Gene=IFNAR2
|Chromosome=21
|position=33241945
|Orientation=plus
|GMAF=0.118
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=IFNAR2
}}{{omim
|id=602376
|rsnum=2229207
|variant=0001
}}

{{ population diversity
| geno1 = (C;C)
| geno2 = (C;T)
| geno3 = (T;T)
| CEU | 0.9 | 13.3 | 85.8
| CHB | 4.7 | 39.5 | 55.8
| JPT | 0.0 | 18.6 | 81.4
| YRI | 0.0 | 10.6 | 89.4
}}

{{ClinVar
|rsid=2229207
|Reversed=0
|FwdREF=T
|FwdALT=C
|REF=T
|ALT=C
|RSPOS=34614250
|CHROM=21
|GMAF=0.1181
|dbSNPBuildID=98
|SSR=0
|SAO=1
|VP=0x05016800000015051f110100
|GENEINFO=IFNAR2:3455
|GENE_NAME=IFNAR2
|GENE_ID=3455
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000021.8:g.34614250T>C
|CLNSRC=OMIM Allelic Variant
|CLNORIGIN=1
|CLNSRCID=602376.0001
|CLNSIG=255
|CLNCUI=C1864880
|CLNDBN=Hepatitis b virus, susceptibility to
|Disease=Hepatitis b virus
|CLNACC=RCV000007711.1
|Tags=PM;PMC;SLO;VLD;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.882; 0.118
|CLNDSDB=MedGen:OMIM
|CLNDSDBID=C1864880:610424
|COMMON=1
}}

{{PMID Auto
|PMID=19434718
|Title=Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|OA=1
}}

{{GET Evidence
|gene=IFNAR2
|aa_change=Phe8Ser
|aa_change_short=F8S
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2229207
|overall_frequency_n=822
|overall_frequency_d=10758
|overall_frequency=0.0764083
|n_genomes=13
|n_genomes_annotated=0
|n_haplomes=14
|n_articles=0
|n_articles_annotated=0
|nblosum100=5
|autoscore=0
|webscore=N
}}

{{on chip | 23andMe v3}}